VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter